Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Sep 14, 2010

Premium

Boston startup Good Start Genetics recently disclosed its management, board of directors, and scientific advisory board. Don Hardison is CEO. He comes to Good Start from Flagship Ventures, where he was an executive in residence. He has also held leadership positions at Laboratory Corporation of America, Exact Corporation, OnTarget, Quest Diagnostics, and SmithKlineBeecham. He received his bachelor's degree from the University of North Carolina, Chapel Hill.

Valerie Greger
is director of genetics research, and comes to Good Start from genetic testing companies Interleukin Genetics and Correlagen Diagnostics. She holds a PhD from the University of Essen, Germany.

Marcia Nizzari is director of informatics, joining the company from Cambridge Research and Instrumentation where she was the director of software development and biomedical applications. She holds an MS in computer science from Boston University.

Greg Porreca, a co-founder, is also the director of technology. He co-developed the Polonator and most recently was a genetics lecturer at Harvard Medical School, and the director of technology for the Personal Genome Project. He holds a PhD in genetics from Harvard University.

Co-founder Paris Wallace is the vice president of finance and operations, joining Good Start after working in finance and operations roles for small companies and in the asset management division at Goldman Sachs. He holds an MBA from Harvard Business School, and a Masters in public affairs from the Harvard Kennedy School.

Good Start's board of directors includes Marc Beer as chairman of the board, who was previously the founder and CEO of ViaCell; Robert Carpenter, who is also the director of Genzyme; Carl Gordon, a founding general partner of OrbiMed; Lutz Giebel, a managing partner at SV Life Sciences; Don Hardison; and Gary Kurtzman, managing director in the life sciences group at Safeguard Scientifics.

The company's scientific advisers include Michael Alper, medical director and reproductive endocrinologist at Boston IVF; George Church, director of the center for computational genetics at Harvard Medical School; Selwyn Oskowitz, reproductive endocrinologist at Boston IVF; Thomas Toth, director of the Vincent In Vitro Fertilization Unit at Massachusetts General Hospital; and Jay Shendure, an assistant professor in the department of genome sciences at the University of Washington.


In connection with SG Biofuels' recent Series A financing, Nathan Wood, the vice president of Life Technologies' genomics technologies business segment, has joined the company's board of directors. Earlier this year, SG Biofuels and Life Technologies collaborated on the sequencing of the jatropha genome.


Complete Genomics has disclosed additional members of its scientific advisory board and its board of directors: Larry Smarr and Michael Rubin.

Smarr, a member of the company's SAB, is the founding director of the California Institute for Telecommunications and Information Technology, and was the founding director of the National Center for Supercomputing Applications until 2000. From 1997 until 2005, he served on the advisory committee to the director of the National Institutes of Health. He holds a PhD in physics from the University of Texas, Austin.

Rubin, who joined Complete's board of directors last month, is a financial analyst at Sands Capital Management, and was previously a resident physician in ophthalmology at the University of Chicago. He holds an MBA from the University of Massachusetts, Amherst, and an MD from the University of Chicago Pritzker School of Medicine.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.